Director/PDMR Shareholding

RNS Number : 2354K

Dechra Pharmaceuticals PLC

19 September 2016

 

The announcement below replaces an announcement released in error on 15 September 2016 under RNS number 9802J. That announcement should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016. In addition, the number of awards for Ian Page have been amended from 73,667 to 73,260 as below.

19 September 2016

Dechra Pharmaceuticals PLC

(the Company)

Director Shareholding

The Company announces that on 19 September 2016 the following Directors were granted awards over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the Plan):

Name of individual	Director	Type of award	Number of shares subject to award
Ian Page	Director	LTIP Award - nil cost option	73,260
Tony Griffin	Director	LTIP Award - Conditional award	20,858

The vesting of all the above awards is subject to the achievement of performance targets.  In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period.  Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance measure.  If the ROCE performance condition is not met, then the LTIP options will lapse in full.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Amendment Previous notification reference number: 3684. The notification should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016. In addition, the number of awards have been amended from 73,667 to 73,260 as below.
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	N/A
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Grant of nil cost options under the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) Nil cost	Volume(s) 73,260
d)	Aggregated information -   Aggregate volume -   Price	N/A
e)	Date of the transaction	2016.09.19
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Tony Griffin
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Amendment Previous notification reference number: 3687. The notification should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016.
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	N/A
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB009633180
b)	Nature of the transaction	Grant of a conditional award under the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) Nil cost	Volume(s) 20,858
d)	Aggregated information -   Aggregate volume -   Price	N/A
e)	Date of the transaction	2016.09.19
f)	Place of the transaction	Outside a trading venue

For further information, please contact:

Suzana Cross, Company Secretary           

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

DSHAKCDKQBKDFCD